Creative Biolabs develops and commercializes a full range of integrated innovative services that are based on phage display technology. We have ...
Creative Biolabs has established custom membrane protein and membrane protein antibody production platforms for antibody discovery...
Creative Biolabs has pushed out a high-throughput B cell sorting platform, which is able to not only screen a large numbers of B-cells from humans or immunized animals but also ...
Creative Biolabs has developed the novel Hyperdoma™ platform, which is a high-throughput hybridoma generation and screening platform based on the advanced ClonePix system. We ...
Creative Biolabs has built a novel single domain antibody and scFv affinity improvement platform using our exclusive HIAF-ProNano™ affinity improvement technology. HIAF-ProNano™ can improve the target binding affinity of single domain antibodies and scFvs substantially by engaging of protein nanocages without changing any of the physico-chemical characteristics of single domain antibodies and scFvs. Great success has been made in improving the binding affinity of single domain antibody and scFv using our HIAF-ProNano™ platform, which infuses the features of protein nanocage with single domain antibodies and scFvs.
Fig. 1 Schoonen and van Hest (2014).
Characteristics of HIAF-ProNanotTM:
• Outstanding affinity improvement capability
• Remarkable homogeneity
• Extraordinary biocompatibility
• Self-assembling and flexible targeting ability
• Highly reproductive targeting operation
• Adjustable molecular level operation
• Multi-functionality
For questions and more information, please contact us at info@creative-biolabs.com
Reference
Schoonen, L. and van Hest, J. C. (2014) 'Functionalization of protein-based nanocages for drug delivery applications', Nanoscale, 6(13), 7124-7141.
Related Sections
Services:Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us